Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?
-
- Gunay Uludag
- Byers Eye Institute, Stanford University, Palo Alto, CA, USA
-
- Muhammad Hassan
- Byers Eye Institute, Stanford University, Palo Alto, CA, USA
-
- Wataru Matsumiya
- Byers Eye Institute, Stanford University, Palo Alto, CA, USA
-
- Brandon Huy Pham
- Byers Eye Institute, Stanford University, Palo Alto, CA, USA
-
- Sophaktra Chea
- Byers Eye Institute, Stanford University, Palo Alto, CA, USA
-
- Ngoc Trong Tuong Than
- Byers Eye Institute, Stanford University, Palo Alto, CA, USA
-
- Hien Luong Doan
- Byers Eye Institute, Stanford University, Palo Alto, CA, USA
-
- Amir Akhavanrezayat
- Byers Eye Institute, Stanford University, Palo Alto, CA, USA
-
- Muhammad Sohail Halim
- Byers Eye Institute, Stanford University, Palo Alto, CA, USA
-
- Diana V Do
- Byers Eye Institute, Stanford University, Palo Alto, CA, USA
-
- Quan Dong Nguyen
- Byers Eye Institute, Stanford University, Palo Alto, CA, USA
収録刊行物
-
- Expert Opinion on Biological Therapy
-
Expert Opinion on Biological Therapy 22 (10), 1275-1291, 2022-07-17
Informa UK Limited
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1360580232186290816
-
- ISSN
- 17447682
- 14712598
-
- データソース種別
-
- Crossref
- KAKEN